Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma
stephanie.dhont2023-02-01T14:21:34+01:00Genoscience Pharma, supported by MATWIN in 2021, receives FDA orphan [...]
February 2023
January 2023
First US leukemia patient dosed with investigational SMART101 cell therapy
stephanie.dhont2023-01-23T15:07:55+01:00Smart Immune announced today that the first adult leukemia patient [...]
Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”
stephanie.dhont2023-01-19T15:25:45+01:00Brenus Pharma, a biotech company specialized in the development of [...]
Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial
stephanie.dhont2023-01-18T10:55:54+01:00Genoscience Pharma announces launch of phase 2b clinical trial of [...]
EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
stephanie.dhont2023-01-17T12:26:28+01:00EverImmune supported by MATWIN in 2022 and interviewed by the [...]
MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.
stephanie.dhont2023-01-17T15:31:53+01:00MPC Therapeutics supported by MATWIN in 2022 and awarded by MATWIN [...]
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancersSmart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
stephanie.dhont2023-01-17T15:31:41+01:00Smart Immune supported by MATWIN in 2022 and awarded “ Best Therapeutic Innovation” [...]
July 2022
Newsletter MATWIN June 2022
stephanie.dhont2022-07-01T10:01:15+02:00Download here the latest MATWIN newsletter :
June 2022
Interview with Karine ROSSIGNOL, CEO Smart-Immune, MATWIN 2022 winner “Best therapeutic innovation”
stephanie.dhont2022-06-29T11:21:58+02:00Introduce us SMARTIMMUNE in a few words Smart Immune, a [...]
International Cancer Cluster Showcase 2022
stephanie.dhont2022-06-28T11:48:48+02:00MATWIN is a partner of the 10th International Cancer Cluster Showcase, international [...]